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In this issue of the Annals of Surgical Oncology
Dr. Wouters et al. add further evidence that outcomes for
patients undergoing esophagectomy are improved when
their surgery is done in a high-volume center. This is an
extremely important and timely manuscript for several
reasons. First, esophageal cancer, particularly esophageal
adenocarcinoma, continues to have the fastest rising inci-
dence in the USA and many Western countries.1 Further,
the precursor condition for adenocarcinoma of the esoph-
agus, Barrett’s esophagus, is also increasing.2 Surveillance
endoscopy for patients with Barrett’s along with the
increasing incidence of Barrett’s has led to an increase in
the number of patients presenting with early-stage esoph-
ageal cancer in many centers. The importance of this trend
is that the survival for patients with superficial esophageal
cancer is completely different from that expected in
patients with a locally advanced tumor. Patients with
superficial cancers can be cured in nearly all circum-
stances, and thus very low procedure-related mortality and
good long-term quality of life are essential.
A second important issue is that there are now excellent
endoscopic alternatives for the therapy of high-grade dys-
plasia and intramucosal esophageal cancer. Endoscopic
resection and ablation has demonstrated efficacy for these
conditions, and some centers are beginning to expand the
role of endoscopic therapy to include patients with low-risk
submucosal tumors.3–5 The rationale for endoscopic ther-
apy of these curable lesions is based largely on the
morbidity and mortality associated with esophagectomy.
Even if it is proven that esophagectomy provides a survival
advantage over endoscopic therapy for early esophageal
cancer, the ease and widespread availability of endoscopic
therapy may make it the preferred approach in many cen-
ters. An important point to consider, though, is that, similar
to esophagectomy, outcomes with endoscopic therapy may
differ between low- and high-volume centers. In fact, it is
likely that treatment in a high-volume endoscopic center
will be as important for a good outcome with endoscopic
therapy as treatment at a high-volume esophageal surgery
center is for a good outcome with esophagectomy.
The increasing incidence of esophageal cancer as well as
the curability of early-stage tumors mandates that esopha-
gectomy be done in centers with low morbidity and
mortality. The results reported by Wouters et al. clearly
demonstrate the benefit of centralization of esophagecto-
mies for cancer in The Netherlands, as well as the impact
of continuous monitoring of clinical outcomes with feed-
back to the centers and surgeons involved. The authors
indicate that the participating Dutch surgeons agreed upon
the scenario of having to refer esophageal cancer patients
to centers with a better outcome if their own results proved
to be unfavorable. This kind of voluntary outcomes
assessment and altruistic referral of patients to other cen-
ters would be challenging to implement in the USA for a
number of reasons. One is that there is a financial disin-
centive with this kind of approach for both physicians and
hospitals. Referral to another center has an impact well
beyond the surgeon, since oncologists, radiation oncolo-
gists, hospitalists, and intensivists as well as radiology and
laboratory services would all be impacted by the loss of
these patients. Second, the USA is geographically much
larger than The Netherlands, and determining where the
regional centers of excellence would be located and how
patients would be transported to these areas would be
complex. Third, many patients in the USA prefer to stay
near home, at a local community hospital with which they
are familiar, rather than go potentially hundreds of miles
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away to an unknown facility, away from family and friends
as well as ministers or other members of their support
group.
Of course, none of these problems are insurmountable.
If malpractice companies stopped providing coverage for
esophagectomies by a low-volume surgeon or insurance
companies stopped paying for esophageal cancer care in a
low-volume or poor-outcome facility this would promptly
address the financial disincentive issues for physicians and
hospitals. Further, as interested as patients often are in
having their health care close to home, they are even more
interested in having it paid for by insurance, and so this
would also encourage patients to find a way to bring their
support group with them to a regional center. This leaves
the issue of how to define a high-volume and good-out-
come center, and here published results from the
experience of Wouters et al. and others, along with data
from the National Surgical Quality Improvement Program
and other national databases such as that maintained by the
Society of Thoracic Surgeons, will begin to set a bench-
mark that can be used to determine centers of excellence.
These centers should be defined, in my opinion, not only on
the basis of volume and short-term outcome, but on dedi-
cation to cancer follow-up, improving long-term outcome
with new and less invasive operations such as the laparo-
scopic vagal-sparing esophagectomy, and a research focus
dedicated to expanding our understanding of the biology of
these tumors and developing novel tests and therapies that
will improve overall survival even further for patients with
this increasing and potentially lethal form of cancer.
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